The US Food and Drug Administration (FDA) has approved Eli Lilly’s Inluriyo (imlunestrant, 200mg tablets), an oral oestrogen receptor antagonist. It is approved for the treatment of adults with oestrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated advanced or metastatic breast cancer (MBC) whose disease progressed after at least one line of […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!